Advisory Panel To Consider Scope Of Indication For Merck's Hep C Drug Boceprevir
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency asks about data on prior null responders and about anemia effects. Merck has proposed a safety monitoring program while avoiding REMS terminology.
You may also be interested in...
Advisory Panel Backs Broad Boceprevir Label, But With Discussion Of Drug's Data Limitations
Members want physicians to make the decision on use for individual Hepatitis C patients despite lack of data on prior null responders.
Advisory Panel Backs Broad Boceprevir Label, But With Discussion Of Drug's Data Limitations
Members want physicians to make the decision on use for individual Hepatitis C patients despite lack of data on prior null responders.
FDA May Grant Advantages For Vertex's Telaprevir Over Merck's Boceprevir
Heading into an Antiviral Products Advisory Committee review April 28, FDA briefing documents indicate some strengths for Vertex's HCV drug over Merck's boceprevir.